|Description||Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction. After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) (P < 0.0001). udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) (P < 0.0001).|
|Synonyms||DA-8159, DA 8159, DA8159, Udenafil, Zydena|
Siguazodan is a selective phosphodiesterase 3 (PDE3) inhibitor (IC50 = 117 nM). Siguazodan acts as a potent vasodilator.
A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.
TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM. It has extremely potent PDE10A inhibitory activity and high selectivity against other PDEs. It is active in the...
Gisadenafil besylate is a potent PDE5 inhibitor (IC50 = 1.23 nM) with >100-fold selectivity for PDE5 over PDE6. Gisadenafil besylate inhibits the breakdown of c...
PF 05180999 is a potent and selective PDE2A inhibitor (IC50 = 1 nM), with 2000-fold selectivity for PDE2A over PDE10A. PF 05180999 was evaluated for schizophren...
Bay 60-7550 is a potent PDE2 inhibitor. It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B...
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis,...
PDE-9 inhibitor is useful for neurodegenerative diseases.